Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet
Steven P Vickers,1 Sharon C Cheetham,1 Katie R Headland,1 Keith Dickinson,1 Rolf Grempler,2 Eric Mayoux,2 Michael Mark,2 Thomas Klein2 1RenaSci, BioCity Nottingham, Nottingham, UK; 2Boehringer Ingelheim Pharma, Biberach an der Riss, Germany Abstract: The present study assessed the potential of the...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7b3c800174874f538ad970f2bff883fa |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7b3c800174874f538ad970f2bff883fa |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:7b3c800174874f538ad970f2bff883fa2021-12-02T04:45:49ZCombination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet1178-7007https://doaj.org/article/7b3c800174874f538ad970f2bff883fa2014-07-01T00:00:00Zhttp://www.dovepress.com/combination-of-the-sodium-glucose-cotransporter-2-inhibitor-empagliflo-a17427https://doaj.org/toc/1178-7007 Steven P Vickers,1 Sharon C Cheetham,1 Katie R Headland,1 Keith Dickinson,1 Rolf Grempler,2 Eric Mayoux,2 Michael Mark,2 Thomas Klein2 1RenaSci, BioCity Nottingham, Nottingham, UK; 2Boehringer Ingelheim Pharma, Biberach an der Riss, Germany Abstract: The present study assessed the potential of the sodium glucose-linked transporter (SGLT)-2 inhibitor empagliflozin to decrease body weight when administered alone or in combination with the clinically effective weight-loss agents orlistat and sibutramine in obese rats fed a cafeteria diet. Female Wistar rats were exposed to a cafeteria diet to induce obesity. Empagliflozin was dosed once daily (10, 30, and 60 mg/kg) for 28 days. Combination studies were subsequently performed using a submaximal empagliflozin dose (10 mg/kg) with either sibutramine or orlistat. Body weight, food, and water intake were recorded daily. The effect of drug treatment on glucose tolerance, relevant plasma parameters, and carcass composition was determined. Empagliflozin dose-dependently reduced body weight, plasma leptin, and body fat though increased urinary glucose excretion. The combination of empagliflozin and orlistat significantly reduced body weight compared to animals treated with either drug alone, and significantly improved glucose tolerance, plasma insulin, and leptin compared to vehicle-treated controls. The effect of sibutramine to improve glycemic control in an oral glucose-tolerance test was also significantly increased, with empagliflozin and combination treatment leading to a reduction in carcass fat greater than that observed with either drug alone. These data demonstrate that empagliflozin reduces body weight in cafeteria-fed obese rats. In combination studies, empagliflozin further improved the body-weight or body-fat loss of animals in comparison to orlistat or sibutramine alone. Such studies may indicate improved strategies for the treatment of obese patients with prediabetes or type 2 diabetes. Keywords: SGLT2, empagliflozin, sibutramine, obesity, rat, combinationVickers SPCheetham SCHeadlKRDickinson KGrempler RMayoux EMark MKlein TDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2014, Iss default, Pp 265-275 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Specialties of internal medicine RC581-951 |
| spellingShingle |
Specialties of internal medicine RC581-951 Vickers SP Cheetham SC Headl KR Dickinson K Grempler R Mayoux E Mark M Klein T Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet |
| description |
Steven P Vickers,1 Sharon C Cheetham,1 Katie R Headland,1 Keith Dickinson,1 Rolf Grempler,2 Eric Mayoux,2 Michael Mark,2 Thomas Klein2 1RenaSci, BioCity Nottingham, Nottingham, UK; 2Boehringer Ingelheim Pharma, Biberach an der Riss, Germany Abstract: The present study assessed the potential of the sodium glucose-linked transporter (SGLT)-2 inhibitor empagliflozin to decrease body weight when administered alone or in combination with the clinically effective weight-loss agents orlistat and sibutramine in obese rats fed a cafeteria diet. Female Wistar rats were exposed to a cafeteria diet to induce obesity. Empagliflozin was dosed once daily (10, 30, and 60 mg/kg) for 28 days. Combination studies were subsequently performed using a submaximal empagliflozin dose (10 mg/kg) with either sibutramine or orlistat. Body weight, food, and water intake were recorded daily. The effect of drug treatment on glucose tolerance, relevant plasma parameters, and carcass composition was determined. Empagliflozin dose-dependently reduced body weight, plasma leptin, and body fat though increased urinary glucose excretion. The combination of empagliflozin and orlistat significantly reduced body weight compared to animals treated with either drug alone, and significantly improved glucose tolerance, plasma insulin, and leptin compared to vehicle-treated controls. The effect of sibutramine to improve glycemic control in an oral glucose-tolerance test was also significantly increased, with empagliflozin and combination treatment leading to a reduction in carcass fat greater than that observed with either drug alone. These data demonstrate that empagliflozin reduces body weight in cafeteria-fed obese rats. In combination studies, empagliflozin further improved the body-weight or body-fat loss of animals in comparison to orlistat or sibutramine alone. Such studies may indicate improved strategies for the treatment of obese patients with prediabetes or type 2 diabetes. Keywords: SGLT2, empagliflozin, sibutramine, obesity, rat, combination |
| format |
article |
| author |
Vickers SP Cheetham SC Headl KR Dickinson K Grempler R Mayoux E Mark M Klein T |
| author_facet |
Vickers SP Cheetham SC Headl KR Dickinson K Grempler R Mayoux E Mark M Klein T |
| author_sort |
Vickers SP |
| title |
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet |
| title_short |
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet |
| title_full |
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet |
| title_fullStr |
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet |
| title_full_unstemmed |
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet |
| title_sort |
combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/7b3c800174874f538ad970f2bff883fa |
| work_keys_str_mv |
AT vickerssp combinationofthesodiumglucosecotransporter2inhibitorempagliflozinwithorlistatorsibutraminefurtherimprovesthebodyweightreductionandglucosehomeostasisofobeseratsfedacafeteriadiet AT cheethamsc combinationofthesodiumglucosecotransporter2inhibitorempagliflozinwithorlistatorsibutraminefurtherimprovesthebodyweightreductionandglucosehomeostasisofobeseratsfedacafeteriadiet AT headl combinationofthesodiumglucosecotransporter2inhibitorempagliflozinwithorlistatorsibutraminefurtherimprovesthebodyweightreductionandglucosehomeostasisofobeseratsfedacafeteriadiet AT kr combinationofthesodiumglucosecotransporter2inhibitorempagliflozinwithorlistatorsibutraminefurtherimprovesthebodyweightreductionandglucosehomeostasisofobeseratsfedacafeteriadiet AT dickinsonk combinationofthesodiumglucosecotransporter2inhibitorempagliflozinwithorlistatorsibutraminefurtherimprovesthebodyweightreductionandglucosehomeostasisofobeseratsfedacafeteriadiet AT gremplerr combinationofthesodiumglucosecotransporter2inhibitorempagliflozinwithorlistatorsibutraminefurtherimprovesthebodyweightreductionandglucosehomeostasisofobeseratsfedacafeteriadiet AT mayouxe combinationofthesodiumglucosecotransporter2inhibitorempagliflozinwithorlistatorsibutraminefurtherimprovesthebodyweightreductionandglucosehomeostasisofobeseratsfedacafeteriadiet AT markm combinationofthesodiumglucosecotransporter2inhibitorempagliflozinwithorlistatorsibutraminefurtherimprovesthebodyweightreductionandglucosehomeostasisofobeseratsfedacafeteriadiet AT kleint combinationofthesodiumglucosecotransporter2inhibitorempagliflozinwithorlistatorsibutraminefurtherimprovesthebodyweightreductionandglucosehomeostasisofobeseratsfedacafeteriadiet |
| _version_ |
1718401089408073728 |